Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4M (up 4506.7% year over year) with net income of −$78M.
Q3 2026 key financials · XBRL
- Revenue
- $4M
- +4506.7% YoY · +9.7% QoQ
- Net income
- −$78M
- −37.2% YoY · −7.0% QoQ
- Operating margin
- -1958.9%
- EPS (diluted)
- −$1.08
- −6.9% YoY · −3.8% QoQ
Source: XBRL data from the 4D Molecular Therapeutics, Inc. (FDMT) Q3 2026 10-Q on SEC EDGAR. USD.
4D Molecular Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $4.1M, up $4.1M YoY, driven by Otsuka clinical development cost sharing and reimbursements
- Net loss $78.1M vs $56.9M YoY, operating loss $81.2M vs $61.2M
- Worst-performing area: 4D-150 R&D expenses $43.1M, up $18.1M YoY
- Cash, equivalents and marketable securities $375.0M, operating cash used $194.8M for nine months
- Topline data expected in Q2 2027 for 4FRONT-1, with additional funding required and losses expected to continue
Risk Factors
- Newly triggered debt risk: June 2026 Hercules Loan Agreement, $20.0 million funded against $200.0 million facility
- Financial risk: $375.0 million in cash, cash equivalents and marketable securities funds planned operations for at least one year
- Regulatory risk: April 2026 proclamation imposes Section 232 tariffs on imported brand pharmaceuticals, biologics and ingredients beginning July 31, 2026
- Operational risk: September 2026 launch of 4SIGHT Phase 3 DME trial creates enrollment and execution exposure
- Competitive risk: Approved therapies from Regeneron, Roche, Vertex and others may hinder physician and payer adoption
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other 4D Molecular Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.